Overcoming immunosuppressive mechanisms

Annals of Oncology

Volumn 19, Issue SUPPL. 7, 2008, Pages

  Widen K ^a   Mozaffari, F ^a   Choudhury, A ^a   Mellstedt, H ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BLP25 VACCINE; CANCER VACCINE; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; DENILEUKIN DIFTITOX; DOCETAXEL; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; IPILIMUMAB; IRINOTECAN; OXALIPLATIN; PEPTIDE VACCINE; TICILIMUMAB; UNCLASSIFIED DRUG; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; DIPHTHERIA TOXIN; HYBRID PROTEIN; LEUKOCYTE ANTIGEN;

ANEMIA; ANTIGEN RECOGNITION; ARTHRITIS; BONE PAIN; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CELLULAR IMMUNITY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DERMATITIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; DRUG RECEPTOR BINDING; ENTEROCOLITIS; ERYTHEMA; FATIGUE; FLU LIKE SYNDROME; GRAFT VERSUS HOST REACTION; HEPATITIS; HUMAN; HYPOPHYSITIS; HYPOTHYROIDISM; IMMUNIZATION; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE REACTION; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOCYTOPENIA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MENINGITIS; MENTAL HEALTH; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NATURAL KILLER CELL; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; POLYARTHRITIS; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; REGULATORY T LYMPHOCYTE; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; SUPPRESSOR CELL; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; URTICARIA; UVEITIS; VITILIGO; ARTICLE; DRUG ANTAGONISM; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; NEOPLASM;

ANTIGENS, CD; DIPHTHERIA TOXIN; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; NEOPLASMS; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, REGULATORY;

EID: 53449090440     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn459     Document Type: Conference Paper

References (26)

1. Kiessling R, Wasserman K, Horiguchi S et al. Tumor-induced immune dysfunction. Cancer Immunol Immunother 1999; 48: 353-362.
2. Guilloux Y, Viret C, Gervois N et al. Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro. Eur J Immunol 1994; 24: 1966-1973.
3. Pawelec G, Heinzel S, Kiessling R et al. Escape mechanisms in tumor immunity: A year 2000 update. Crit Rev Oncog 2000; 11: 97-133.
4. Roncarolo MG, Bacchetta R, Bordignon C et al. Type 1 T regulatory cells. Immunol Rev 2001; 182: 68-79.
5. Liyanage UK, Moore TT, Joo HG et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169: 2756-2761.
6. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949.
7. Shimizu J, Yamazaki S, Takahashi T et al. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002; 3: 135-142.
8. Zheng Y, Rudensky AY. Foxp3 in control of the regulatory T cell lineage. Nat Immunol 2007; 8: 457-462.
9. Miyara M, Sakaguchi S. Natural regulatory T cells: Mechanisms of suppression. Trends Mol Med 2007; 13: 108-116.
10. Deaglio S, Dwyer KM, Gao W et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257-1265.
11. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006; 16: 53-65.
12. Gulley JL, Arlen PM, Bastian A et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005; 11: 3353-3362.
13. Liu JY, Wu Y, Zhang XS et al. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother 2007; 56: 1597-1604.
14. Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346-2357.
15. North S, Butts C. Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. Expert Rev Vaccines 2005; 4: 249-257.
16. Ghiringhelli F, Menard C, Puig PE et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56: 641-648.
17. Lord R, Nair S, Schache A et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: A phase II study. J Urol 2007; 177: 2136-2140, discussion 2140.
18. Correale P, Cusi MG, Tsang KY et al. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol 2005; 23: 8950-8958.
19. Weihrauch MR, Ansen S, Jurkiewicz E et al. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin Cancer Res 2005; 11: 5993-6001.
20. Wong BY, Gregory SA, Dang NH. Denileukin diftitox as novel targeted therapy for lymphoid malignancies. Cancer Invest 2007; 25: 495-501.
21. Litzinger MT, Fernando R, Curiel TJ et al. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 2007; 110: 3192-3201.
22. Barnett B, Kryczek I, Cheng P et al. Regulatory T cells in ovarian cancer: Biology and therapeutic potential. Am J Reprod Immunol 2005; 54: 369-377.
23. Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115: 3623-3633.
24. Mahnke K, Schonfeld K, Fondel S et al. Depletion of CD4+CD25+ human regulatory T cells in vivo: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 2007; 120: 2723-2733.
25. Attia P, Maker AV, Haworth LR et al. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 2005; 28: 582-592.
26. Cranmer LD, Hersh E. The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest 2007; 25: 613-631.